Chronisch-entzündliche Darmerkrankungen beim Hund – diagnostische und therapeutische Aspekte

Erdmann, Carolin; Heilmann, Romy M.

doi:10.15654/tpk-170366

Cited by 10 publications

(4 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usual diagnostic workup and therapeutic approach for CIEs are often modified in the case of hypoalbuminemia. Gut biopsies are usually taken immediately for histological examination and, instead of using a sequential treatment approach, immunosuppressants (mostly glucocorticoids and chlorambucil) are often started early, in combination with a highly digestible, ultra-low-fat diet, with or without antibiotics [ 1 , 24 , 25 , 26 , 27 ]. In addition, PLEs are frequently complicated with a hypercoagulable state and consequently require thromboprophylactic treatment [ 28 ].…”

Section: Current Classification Of Ciesmentioning

confidence: 99%

Updating the Classification of Chronic Inflammatory Enteropathies in Dogs

Dupouy-Manescau,

Méric,

Sénécat

et al. 2024

Animals

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIEs) in dogs are currently classified based on response to sequential treatment trials into food-responsive (FREs); antibiotic-responsive (AREs); immunosuppressant-responsive (IREs); and non-responsive enteropathies (NREs). Recent studies have reported that a proportion of NRE dogs ultimately respond to further dietary trials and are subsequently misclassified. The FRE subset among CIEs is therefore probably underestimated. Moreover, alterations in the gut microbiota composition and function (dysbiosis) have been shown to be involved in CIE pathogenesis in recent research on dogs. Metronidazole and other antibiotics that have been used for decades for dogs with AREs have been demonstrated to result in increased antimicrobial resistance and deleterious effects on the gut microbiota. As a consequence, the clinical approach to CIEs has evolved in recent years toward the gradual abandonment of the use of antibiotics and their replacement by other treatments with the aim of restoring a diverse and functional gut microbiota. We propose here to refine the classification of canine CIEs by replacing the AREs category with a microbiota-related modulation-responsive enteropathies (MrMREs) category.

show abstract

Section: Current Classification Of Ciesmentioning

confidence: 99%

Updating the Classification of Chronic Inflammatory Enteropathies in Dogs

Dupouy-Manescau,

Méric,

Sénécat

et al. 2024

Animals

View full text Add to dashboard Cite

show abstract

“…In dogs with PLE, if there is no strong indication of an immune-mediated etiology, immunosuppressive therapy should not be a first option and should be carefully applied after a non-responsive nutrition modification trial [4,41,42]. The use of supplemental medication such as pro-/prebiotics, gastroprotectors, and antiemetics may also benefit IBD patients [43][44][45]. It is important to correct any possible imbalance, for example, Vitamin B12 deficiency and supportive care.…”

Section: Conventional Therapiesmentioning

confidence: 99%

A Comprehensive Exploration of Therapeutic Strategies in Inflammatory Bowel Diseases: Insights from Human and Animal Studies

Dias,

Franchi-Mendes

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a collective term for a group of chronic inflammatory enteropathies which are characterized by intestinal inflammation and persistent or frequent gastrointestinal signs. This disease affects more than 3.5 million humans worldwide and presents some similarities between animal species, in particular, dogs and cats. Although the underlying mechanism that triggers the disease is not yet well understood, the evidence suggests a multifactorial etiology implicating genetic causes, environmental factors, microbiota imbalance, and mucosa immune defects, both in humans and in dogs and cats. Conventional immunomodulatory drug therapies, such as glucocorticoids or immunosuppressants, are related with numerous adverse effects that limit its long-term use, creating the need to develop new therapeutic strategies. Mesenchymal stromal cells (MSCs) emerge as a promising alternative that attenuates intestinal inflammation by modulating inflammatory cytokines in inflamed tissues, and also due to their pro-angiogenic, anti-apoptotic, anti-fibrotic, regenerative, anti-tumor, and anti-microbial potential. However, this therapeutic approach may have important limitations regarding the lack of studies, namely in veterinary medicine, lack of standardized protocols, and high economic cost. This review summarizes the main differences and similarities between human, canine, and feline IBD, as well as the potential treatment and future prospects of MSCs.

show abstract

“…Chronic inflammatory enteropathies (CIE) are a group of common disorders in dogs, which are categorized based on the patient’s response to treatment as either food-responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD), or idiopathic inflammatory bowel disease (IBD) [1–4]. Dogs with FRD will show a complete clinical response after dietary modification to a novel source of protein and carbohydrates or to a commercially available hydrolyzed protein diet [5,6], whereas dogs with ARD require the use of antibiotic treatment, for example with tylosin, in addition to dietary management for clinical signs of gastrointestinal disease to resolve [7–9].…”

Section: Introductionmentioning

confidence: 99%

“…Dogs with FRD will show a complete clinical response after dietary modification to a novel source of protein and carbohydrates or to a commercially available hydrolyzed protein diet [5,6], whereas dogs with ARD require the use of antibiotic treatment, for example with tylosin, in addition to dietary management for clinical signs of gastrointestinal disease to resolve [7–9]. Idiopathic IBD is defined as chronic gastrointestinal signs of a complex pathogenesis, histologic confirmation of intestinal inflammation, and the necessity for anti-inflammatory and / or immunosuppressive treatment [2,4,7,10]. To date, the etiopathogenesis of CIE, in particular of idiopathic IBD, has not been fully unraveled.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment

Kalenyak¹,

Heilmann²,

Lest

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Background Inflammatory bowel disease (IBD) and food-responsive diarrhea (FRD) are common chronic enteropathies in dogs, of which the exact pathogenesis has not been fully understood. In people dyslipidemia has been reported in patients with IBD, and potential therapeutic benefits of polyunsaturated fatty acids (PUFA) in the treatment of IBD have been investigated. Studies on the phospholipid profile in dogs with IBD and FRD are still lacking. Aim To investigate the systemic phospholipid profile of dogs with IBD or FRD and to evaluate possible differences in phospholipids before and after treatment. Methods The phospholipids in whole blood and EDTA plasma of 32 dogs diagnosed with either IBD (n = 16) or FRD (n = 16) were analyzed by hydrophilic interaction liquid chromatography (HILIC) prior to and after initiation of treatment, which included an elimination diet enriched with PUFAs. Results A clear separation of the phospholipids between whole blood and plasma was demonstrated on principal component analysis plots. In addition to the type of specimen, treatment and disease severity were the most significant factors determining the variance of the phospholipid profile. An increase in lysolipids was observed after treatment. The phosphatidylcholine (PC) species changed from PC 38:4 before treatment to mainly lysophosphatidylcholine 18:0 after treatment. Furthermore, several differences in the abundance of individual phospholipids were identified between dogs with IBD and dogs with FRD and between treatment statuses using random forest analysis. Conclusion Significant variances were identified in the phospholipid profiles of dogs with IBD and FRD. These were particularly determined by type of specimen used, disease severity and treatment status. After treatment, a shift of phospholipid species towards lysophosphatidylcholine 18:0 was observed. Future studies should further investigate the role of lipids in the pathophysiology of IBD and FRD as well as their potential therapeutic benefits.

show abstract

Chronisch-entzündliche Darmerkrankungen beim Hund – diagnostische und therapeutische Aspekte

Cited by 10 publications

References 111 publications

Updating the Classification of Chronic Inflammatory Enteropathies in Dogs

Updating the Classification of Chronic Inflammatory Enteropathies in Dogs

A Comprehensive Exploration of Therapeutic Strategies in Inflammatory Bowel Diseases: Insights from Human and Animal Studies

Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment

Contact Info

Product

Resources

About